The FDA last week approved AstraZeneca and Merck’s Lynparza for use in some treatment-resistant prostate cancers — the PARP inhibitor’s fourth oncology nod. For the treatment of triple-negative breast cancer, Lynparza currently holds preferred status for 4% of covered lives under the pharmacy benefit, growing to 41% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 5/20/20